Epigallocatechin-3-gallate protects against osteoarthritis-induced chondrocytes dysfunction by regulating PLa2g2a
Frontiers in Pharmacology · 13.08.2025 · 16
DOI: 10.3389/fphar.2025.1624818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.08.2025. Verfasst von Mengyuan Dai und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, Center for Immunology and Hematology and General Practice Ward/…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Plan Projects of Tibet Autonomous Region.
Abstract (Originalsprache)
Background
Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage erosion, subchondral bone remodeling, and synovial inflammation. OA progression is driven by an imbalance between anabolic and catabolic activities in the cartilage extracellular matrix (ECM). Identifying molecular targets involved in chondrocyte (responsible for ECM homeostasis in OA) dysfunction is therefore essential for developing effective OA treatments. Notably, epigallocatechin-3-gallate (EGCG), a polyphenolic compound derived from green tea, is a known pan-assay interference compound (PAINS), which may produce non-specific in vitro effects (e.g., protein binding, redox interference) that challenge the interpretation of its pharmacological relevance. Thus, multi-dimensional validation ( in vitro + in vivo + transcriptomic) is critical to mitigate such limitations.
Methods
We investigated the effects of epigallocatechin-3-gallate (EGCG), a polyphenolic compound derived from green tea, on OA-induced dysfunction in chondrocytes. Primary chondrocytes, extracted from the knee joints of rats and constructed an OA model via IL-1β stimulation, observed cell viability and morphology upon EGCG treatment. Transcriptomic analysis was conducted to screen for differentially expressed genes. Subsequently, an OA model in rats was induced by intra-articular injection of monoiodoacetic acid (MIA), and EGCG was administered for OA treatment to validate the expression of the differentially expressed genes.
Results
EGCG could reduce reactive oxygen species (ROS) levels and decreased the expression of inflammatory cytokines IL-β, MMP13, and TNF-α. Transcriptome analysis identified differentially expressed genes, and network pharmacology pinpointed Pla2g2a as a key target of EGCG. Molecular docking studies confirmed a strong binding affinity between EGCG and Pla2g2a. OA model demonstrated that EGCG treatment significantly promoted cartilage repair and increased Pla2g2a expression. In vivo experiments demonstrated that EGCG treatment significantly promoted cartilage repair and upregulated Pla2g2a expression, consistent with in vitro and transcriptomic findings—suggesting the observed effects are not solely due to PAINS interference.
Conclusion
These findings underscore the therapeutic potential of EGCG in OA management via antioxidative, anti-inflammatory properties, and Pla2g2a-mediated modulation. Notably, the consistency across in vitro , in vivo, and transcriptomic data supports the biological relevance of EGCG’s effects, despite its PAINS characteristics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, Center for Immunology and Hematology and General Practice Ward/International Medical Center Ward, General Practice Medical Center, We…
- Science and Education Section, Hospital of Chengdu Office of People's Government of Xizang Autonomous Region (Hospital.C.X.), Chengdu, Sichuan, China.
- Medical College, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- Biological Sample Bank, Hospital of Chengdu Office of People's Government of Xizang Autonomous Region (Hospital.C.X.), Chengdu, China.
- National Engineering Laboratory for Clean Technology of Leather Manufacture, College of Biomass Science and Engineering, Sichuan University, Chengdu, Sichuan, China.
- Department of Orthopedics, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Förderung
- Science and Technology Plan Projects of Tibet Autonomous Region
Zitieren
APA
Dai, M., Shi, J., Wang, T., Wan, S., Fan, C., Wang, S., Chen, S., Shang, J., & Kong, Q. (2025). Epigallocatechin-3-gallate protects against osteoarthritis-induced chondrocytes dysfunction by regulating PLa2g2a. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1624818
Vancouver
Dai M, Shi J, Wang T, Wan S, Fan C, Wang S, et al. Epigallocatechin-3-gallate protects against osteoarthritis-induced chondrocytes dysfunction by regulating PLa2g2a. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1624818
BibTeX
@article{Dai2025,
author = {Dai, Mengyuan and Shi, Jing and Wang, Tao and Wan, Sha and Fan, Chen and Wang, Siyu and Chen, Siyuan and Shang, Jiaojiao and Kong, Qingquan},
title = {Epigallocatechin-3-gallate protects against osteoarthritis-induced chondrocytes dysfunction by regulating PLa2g2a},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1624818}
}
EUVIMED